It has been also demonstrated that Paclitaxel, especially in fractionated regimens, exploits anti-angiogenic mechanisms of action [25] Together, these chemotherapy-related aspects, in addition to pre-clinical and clinical studies linking TP53 mutations to the VEGF pathway [5,6,7,8] and anti-VEGF/VEGFR systemic therapies [9,10,11,12,13,14,15], contribute to explaining the favorable results of the Ramucirumab/Paclitaxel combination in metastatic gastric cancers harboring TP53 mutations. Here, KDR is linked to gastric cancer.